Treatment response to daratumumab in antibody-mediated kidney allograft rejection: evidence from serial protocol biopsies Authors: Nele Kirsten Kanzelmeyer, Murielle Verboom, Michael Hallensleben, Christina Bade-Döding, Anne Schön, Dieter Haffner, Jan Hinrich Bräsen, Anette Melk Published: 2026 ABSTRACT ABSTRACTBackgroundAntibody-mediated rejection (ABMR) is a major cause of chronic allograft dysfunction and graft loss after kidney transplantation (KTx). Daratumumab, antibody targeting the transmembrane glycoprotein CD38 (cluster of differentiation) on immune cells, has shown promise in the treatment of refractory ABMR in adult solid organ transplantation; however, pediatric data are scarce.MethodsWe report two pediatric cases of refractory ABMR after KTx treated with daratumumab with followed-up protocol biopsies over 10–12 months. Treatment consisted of an induction phase with five weekly doses followed by maintenance dosing every two to four weeks. Donor-specific antibodies (DSAs), kidney function, albuminuria, and histologic response were assessed.ResultsThe first case, a 10-year-old girl with recurrent ABMR after KTx showed histologic improvement from active ABMR with C4d positivity, glomerulitis, and severe microvascular inflammation to predominantly chronic changes without signs of active rejection. Microvascular inflammation became mild and C4d staining turned negative. The second case, a 9-year-old boy with active and chronic antiglomerular basement membrane disease and severe transplant ABMR glomerulopathy initially showed progression of chronic injury, followed by complete histologic resolution of active disease, disappearance of C4d staining, minimal fibrosis (<1%), and marked reduction of albuminuria after 10 months. Both patients demonstrated reduced DSA levels, stabilization of graft function, and no serious adverse events.ConclusionDaratumumab was associated with histologic improvement, reduction of microvascular inflammation, and stabilization of graft function in two children with refractory ABMR after KTx. Controlled studies to determine the safety, efficacy, and optimal dosage of daratumumab in children with ABMR are needed. What was known: ABMR is a leading cause of chronic allograft dysfunction and graft loss after KTx, and effective treatment options for refractory ABMR remain limited. ABMR is a leading cause of chronic allograft dysfunction and graft loss after KTx, and effective treatment options for refractory ABMR remain limited. Daratumumab, an anti-CD38 monoclonal antibody, has shown encouraging results in adults with refractory ABMR after solid organ transplantation. Daratumumab, an anti-CD38 monoclonal antibody, has shown encouraging results in adults with refractory ABMR after solid organ transplantation. Evidence for the use of daratumumab in children is extremely limited, and its histological effects, safety, and optimal treatment regimen in pediatric kidney transplant recipients are largely unknown. Evidence for the use of daratumumab in children is extremely limited, and its histological effects, safety, and optimal treatment regimen in pediatric kidney transplant recipients are largely unknown. This study adds: In our cases, we observed regression of active histological rejection, a reduction in DSAs, and stabilization of graft function. In our cases, we observed regression of active histological rejection, a reduction in DSAs, and stabilization of graft function. Serial protocol biopsies showed marked reduction of microvascular inflammation, disappearance of C4d staining, and transition from active rejection to predominantly chronic or resolved lesions. Serial protocol biopsies showed marked reduction of microvascular inflammation, disappearance of C4d staining, and transition from active rejection to predominantly chronic or resolved lesions. Daratumumab was well tolerated in our patients, supporting its potential as a rescue therapy for refractory pediatric ABMR while highlighting the need for prospective controlled studies. Daratumumab was well tolerated in our patients, supporting its potential as a rescue therapy for refractory pediatric ABMR while highlighting the need for prospective controlled studies. Potential impact: Daratumumab may represent a promising treatment option for children with refractory ABMR when conventional therapies have failed. Daratumumab may represent a promising treatment option for children with refractory ABMR when conventional therapies have failed. INTRODUCTION Antibody-mediated rejection (ABMR) remains one of the major causes of late graft dysfunction and graft loss after kidney transplantation (KTx). Despite the availability of established therapeutic strategies—including plasmapheresis, intravenous immunoglobulins, CD20 (cluster of differentiation)-directed B-cell depleting therapies like rituximab, proteasome inhibitors, and complement-directed therapies are largely based on expert consensus recommendations from the Transplantation Society Working Group rather than robust randomized controlled trial data. Importantly, none of these approaches has yet demonstrated a clinically meaningful long-term benefit in ABMR beyond partial effects on donor-specific antibody (DSA) persistence and short-term immunological responses [1]. Despite these treatment options, a substantial proportion of patients develop persistent or refractory ABMR, driven by DSA production from long-lived plasma cells. DSAs frequently demonstrate an inadequate response to conventional CD20-directed B-cell-depleting therapies, thereby emphasizing the urgent clinical necessity for therapies that more effectively target antibody-producing cells. Daratumumab, a monoclonal antibody directed against CD38, offers a mechanistically distinct approach by targeting plasma cells directly. CD38 is highly expressed on mature plasma cells and plasma blasts, providing a biological rationale for its use in ABMR, particularly in cases characterized by persistent DSA production despite standard immunosuppressive and antibody-directed therapies. In addition to plasma cell depletion and reduction of antibody production, the effects of daratumumab may also involve depletion of CD38-expressing natural killer cells, which are increasingly recognized as important mediators of microvascular inflammation and ABMR-associated graft injury [2, 3]. In recent years, we have seen an increased exploration of daratumumab as a rescue or adjunctive therapy in solid organ transplantation, where the risk of rejection is high. This review summarizes the current literature on daratumumab in the treatment of ABMR and discusses the reported clinical findings with regard to their potential relevance for adult and pediatric transplant recipients (Table 1). In addition, we report the clinical course of two pediatric kidney transplant recipients from our center who developed refractory ABMR and were treated with daratumumab, following the treatment protocol established by our adult nephrology colleagues with a follow-up period of 1 year. The aim of this integrated review and case presentation is to provide a comprehensive overview of the available evidence and to illustrate the potential benefits, limitations, and safety aspects of daratumumab for treatment of ABMR after KTx in children. Table 1:Summary of published case reports and case series on the use of daratumumab for the treatment of ABMR following organ transplantation. The table presents patient population, number of patients, transplanted organ, indication, therapeutic strategy, and reported clinical, histological, serological, and molecular outcomes.Author (Year)PopulationPatients n=Transplanted organIndicationTherapyKey outcomesConnolly et al. (2025)Pediatric1KidneyABMRDaratumumabImproved graft function, reduction in DSA, stabilization of rejectionKwun et al. (2019)Adults2Kidney and heartRefractory ABMR/high highly sensitizedDaratumumabReduced DSA; reduced anti-HLA antibodiesDoberer et al. (2021)Adults1KidneyLate, chronic ABMRDaratumumabDSA reduction, resolution of microvascular inflammation, stabilised graft functionZhu et al. (2023)Adults2KidneyLate, chronic ABMRDaratumumab, plasmapheresis, immunglobulinDSA reduction, partialrecovery or stabilization of graft functionSpica et al. (2019)Adults1ABO-incompatiblekidneyABMRDaratumumab as rescue therapyABMR, reduction of blood group antibody titers and improved graft functionLye et al. (2025)Adults16KidneyChronic active ABMRDaratumumabReduced microvascular inflammation, eGFR remained stable, proteinuria improved, dd-cfDNA decreased, DSA negativede Nattes et al. (2023)Adults1KidneyActive ABMRDaratumumabRegression of the molecular signature of ABMRSüsal et al. (2023)Adults1Kidney (ABO- and HLA-incompatible)Early ABMRBlood group-specific apheresis DaratumumabFull recovery graft functionOllé et al. (2025)Adults1KidneyLate, chronic ABMRDaratumumab as rescue therapyDSA negative, reduced microvascular inflammationLesan et al. (2024)Adults1Stem cellsPrimary graft failure (DSA-mediated)Desensitization regimen including plasmapheresis, immunoglobulin, daratumumabEffective desensitization optionMilligan et al. (2025)Pediatric12HeartDesensitization n = 3/ABMR n = 9DaratumumabDecline in cPRA in patients needed desensitization/ABMR patients improved ABMRFenton et al. (2022)Pediatric1HeartABMRPlasmapheresis, immunglobulins, rituximab, daratumumabTransient DSA reductionAguilera Agudo et al. (2021)Adults1HeartABMRImmunoadsorption, daratumumab, methylprednisolonNo capillary injuries, no deposits, slight reduction of DSAHillebrand et al. (2025)Adults14LungABMRDaratumumabDSA decreased, 11 patients survivedLemal et al. (2024)Adults6Kidney (n = 5), heart (n = 1)Sensitization/ABMRDaratumumabDecreased DSAOsmanodja et al. (2024)Adults2KidneyABMRDaratumumabStabilization of eGFR, decline of dd-cfDNAGuo et al. (2025)Adults7KidneyLate, chronic ABMRDaratumumab, tocilizumabDSA reduction and graft function stabilization, remission of microvascular inflammationcPRA = calculated panel reactive antibody. Summary of published case reports and case series on the use of daratumumab for the treatment of ABMR following organ transplantation. The table presents patient population, number of patients, transplanted organ, indication, therapeutic strategy, and reported clinical, histological, serological, and molecular outcomes. cPRA = calculated panel reactive antibody. To date, the published evidence consists mainly of small case series and individual case reports. Nevertheless, the available data suggest that daratumumab can effectively modulate plasma cell activity, leading not only to reductions in circulating DSA levels but also to improvements or stabilization of graft function and, in several reports, favorable changes in histological features of ABMR. Daratumumab in pediatric kidney transplantation The evidence supporting the use of daratumumab for ABMR in pediatric kidney transplant recipients remains extremely limited. To date, only a single pediatric case has been reported by Connolly et al. [4], describing a child with refractory ABMR after KTx in whom conventional therapies had failed. Following daratumumab treatment, the patient demonstrated improved graft function, a reduction in DSA levels, and stabilization of the rejection process, suggesting that CD38-directed plasma cell depletion may also be effective in the pediatric population. Kwun et al. provided a detailed mechanistic framework for targeting CD38-expressing plasma cells in sensitized kidney transplant recipients, highlighting the limitations of CD20-directed therapies in eliminating long-lived antibody-producing cells. Their work established the biological rationale for the use of daratumumab in ABMR, while also emphasizing potential limitations such as incomplete plasma cell depletion and the risk of antibody rebound [5]. Despite these encouraging insights, long-term outcome data are lacking, and safety concerns related to profound immunosuppression, infection risk, and hematological adverse effects remain largely unresolved in the pediatric setting. Daratumumab in adult kidney transplantation Several reports have documented the use of daratumumab in adult kidney transplant recipients with acute, chronic active, or refractory ABMR. Doberer et al. [6] were the first to describe successful treatment of chronic active ABMR with daratumumab, reporting not only reductions in DSA levels but also histological improvement and stabilization of graft function. Zhu et al. [7] subsequently reported additional cases of late or chronic ABMR associated with de novo DSA, in which partial recovery or stabilization of graft function and decreases in antibody titers were observed. Spica et al. [8] demonstrated the efficacy of daratumumab in a case of refractory ABMR following ABO (blood group system)-incompatible KTx, with resolution of rejection and improvement in graft function. Further insights into the rationale for plasma cell-directed therapies in persistent humoral rejection were provided by Lye and Loh [9] and de Nattes et al. [10], who emphasized the central role of long-lived plasma cells in sustained antibody production. Süsal et al. [11] described the use of daratumumab in combination with blood group-specific apheresis as rescue therapy for acute ABMR in ABO- and human leukocyte antigen (HLA)-incompatible KTx, while Ollé et al. [12] explored dose optimization strategies aimed at achieving effective plasma cell depletion. Lesan et al. [13] reported successful treatment of donor-specific HLA antibody-mediated primary graft failure using daratumumab, underscoring its potential role in severe and refractory antibody-mediated graft injury. Across adult studies, dosing regimens varied considerably with respect to total dose, frequency, and treatment duration, reflecting the experimental nature of daratumumab use in transplantation. This heterogeneity complicates direct comparison of outcomes but also highlights the need for standardized treatment protocols, particularly when translating these approaches to pediatric patients. Daratumumab in other solid organ transplantation Beyond KTx, daratumumab has also been administered in cases of refractory ABMR following heart and lung transplantation. Milligan et al. [14] reported its use in desensitization protocols and in the treatment of ABMR in pediatric heart transplant recipients, with transient improvements in antibody levels and graft function. Similarly, Fenton et al. [15] described a temporary response to daratumumab therapy in pediatric orthotopic heart transplantation, while Aguilera Agudo et al. [16] reported successful treatment of ABMR after heart transplantation. In lung transplantation, Hillebrand et al. [17] described a single-center experience with CD38-targeted therapy, noting partial responses and variability in efficacy. Lemal et al. [18] subsequently reported on a series of six highly sensitized solid organ transplant recipients, reinforcing the feasibility and overall tolerability of daratumumab across different transplant settings. Across all reported indications, daratumumab has predominantly been used in severe cases of acute, chronic, or refractory ABMR. The drug consistently achieved temporary plasma cell depletion, reductions in circulating DSA, and—importantly in several reports—stabilization or improvement of graft function and histological features of rejection. However, the durability of these effects remains uncertain. Safety considerations are of particular importance, especially in pediatric patients. Reported adverse events include cytopenia, hypogammaglobulinemia, and an increased susceptibility to infections. Patients with pre-existing cytopenia, recurrent or severe infections, or extensive prior immunosuppressive exposure may be at higher risk for treatment-related complications. Careful patient selection, close monitoring, and prophylactic strategies are therefore essential when considering daratumumab therapy. Overall, while the available data suggest potential benefit, evidence in pediatric KTx remains limited to a single published case, underscoring the need for systematic data collection and longer-term follow-up. CASE DESCRIPTIONS Case 1 Baseline and transplant course We present the case of a 10-year-old girl with end-stage kidney disease due to renal dysplasia (clinical characteristics summarized in Table 2). She underwent a kidney transplant from a deceased donor at the age of 2, after 2 months of peritoneal dialysis. Pretransplant immunological assessment revealed no HLA antibodies and all cell cultures were negative for lymphocyte toxic crossmatches. The HLA mismatch score (A–B–C–DRB1–DQB1) was 2–2–1–1–0. Induction therapy consisted of basiliximab, followed by maintenance immunosuppression with cyclosporine A (CSA), everolimus, and corticosteroids. Post-transplant, the graft function was excellent, with the patient’s serum creatinine level decreasing from 278 to 43 µmol/l. The early post-transplant course was uneventful. Corticosteroids were tapered and discontinued 6 months after KTx. A protocol biopsy performed at this time revealed borderline rejection, which was treated with corticosteroid pulse therapy. Maintenance immunosuppression was continued unchanged. During follow-up, however, the patient developed severe arterial hypertension, requiring quadruple antihypertensive therapy. Development and diagnosis of ABMR Serial DSA monitoring showed no detectable antibodies 6 months after transplant. De novo DSAs were first detected 2 years after the transplant, targeting HLA-DR7, DR9, and DR53. Antibody levels subsequently fluctuated, with transient negativity followed by the reappearance of DSA targeting HLA-DR53, and subsequently HLA-DR7. Non-HLA antibodies [ETAR (endothelin-1 type A receptor) and AT1R (Angiotensin II type 1 receptor)] were first detected 4 years after the transplant, at levels exceeding the upper detection limit (>40 U/ml). Six years post-transplant, a kidney biopsy was performed because of declining graft function revealing acute ABMR combined with borderline T-cell-mediated rejection, consistent with the Banff criteria. At that time, the estimated glomerular filtration rate (eGFR) according to the Schwartz formula (2009) had declined from 55 to ∼40 ml/min/1.73 m2 (milliliters per minute, square meters). Prior therapies Prior therapies, which were administered specifically to treat this initial episode of ABMR, consisted of four doses of intravenous immunoglobulins and two doses of rituximab. Following therapy, serum creatinine stabilized at 70–80 µmol/l (eGFR 40–57) for ∼2 years. Daratumumab regimen Eight years after KTx, graft function deteriorated again (serum creatinine 90–100 µmol/l) and a repeat biopsy confirmed ABMR with persistent DSA against HLA-DR7 (Fig. 1). The patient received steroid pulse therapy, two cycles of immunoadsorption, and daratumumab. Daratumumab (16 mg/kg of body weight) was administered following a premedication regimen of prednisolone and clemastine. The dosing schedule consisted of weekly administration for the first five doses, followed by two doses given at 14-day intervals, and concluding with five doses administered every 5 months. Additionally, while the specific agents used for maintenance immunosuppression were not changed, the regimen was subsequently managed with higher target trough levels. Clinical course of Patient 1 following the diagnosis of ABMR and treatment with daratumumab. The figure depicts longitudinal changes in eGFR (green), serum IgG (turquoise), DSA-MFI (black), and urinary albumin-to-creatinine ratio (blue) over time (days since ABMR diagnosis). Orange vertical bars represent individual daratumumab administrations. Following initial therapy, IgG levels declined markedly, accompanied by a reduction in albuminuria and stabilization of eGFR. DSA-MFI decreased to negative levels over the course of treatment. Follow-up: DSA, renal function, and histology Serial kidney biopsies demonstrated a gradual histological response to therapy (Fig. 2). Figure 1 shows representative images depicting ABMR in initial biopsy (A–C) and final biopsy after daratumumab therapy (D). Glomerulitis (arrows) and peritubular capillaritis (arrowheads) can be seen in panel (A), glomerular double contours are shown in panel (B) (small arrows) and C4d positivity (long arrows) in panel (C). Following daratumumab treatment (D), only remnant peritubular capillaritis was evident (arrowheads) without glomerulitis. PAS (periodic acid–Schiff) staining in panels (A) and (D); Jones methenamine silver staining in panel (B); immunohistochemistry for C4d using antibody from Ventana (RTU) with DAB (3,3′-diaminobenzidine) chromogen detection in panel (C); bars indicate 50 micrometers in panels (A), (C), and (D), as well as 20 micrometers in panel (B). Baseline biopsy (Table 3) Active ABMR with microvascular inflammation and C4d positivity in the presence of established chronic transplant glomerulopathy (cg2) and moderate mesangial matrix expansion (mm3). Chronic tubulointerstitial injury was limited (ci0, ct1), while vascular chronicity was mild (cv1). DSA-mean fluorescence intensity (MFI) was 2425. Three months Active and chronic active ABMR with ongoing severe glomerulitis and peritubular capillaritis (\u2009g3, ptc3), persistent transplant glomerulopathy (cg2), and continued C4d positivity (C4d1). Chronic injury parameters remained largely unchanged (ci0, ct1). At this time point, DSA became undetectable. Six months Mixed acute and chronic ABMR with persistent microvascular inflammation including resolution of glomerulitis (g0) and reduction of peritubular capillaritis (ptc2). C4d staining was negative (C4d0). Chronic transplant glomerulopathy persisted (cg2) together with mesangial matrix expansion (mm3). Mild progression of chronic injury became apparent (ci1, ct1, ti1) with low-grade arteriolar hyalinosis (ah1). DSA remained negative. Ten months The biopsy was performed 3 months after the end of daratumumab treatment. No evidence of active ABMR; C4d negative; minimal residual peritubular capillaritis; and predominantly chronic changes including mesangial hypercellularity and vascular sclerosis. Chronic lesions remained stable, including transplant glomerulopathy (cg2) and mesangial matrix expansion (mm3) moderateInterstitial Fibrosis and Tubular Atrophy (IFTA) (∼25%), while mild chronic interstitial injury persisted (ci1, ct1, ti1). Moderate arteriolar hyalinosis was present (ah2). After initiation of daratumumab-based therapy, donor-derived cell-free DNA (dd-cfDNA) was measured at 1%. dd-cfDNA measurements were performed only at later follow-up time points, as this recently established and resource-intensive assay is currently primarily used at our center for surveillance of rejection recurrence rather than for serial monitoring of therapeutic response to daratumumab. No infusion-related reactions, cytopenias, or infectious complications occurred during daratumumab therapy. The only relevant treatment-related adverse event was hypogammaglobulinemia with reduced immunoglobulin G (IgG) levels, which required immunoglobulin substitution therapy. Additionally, cotrimoxazole was administered as prophylaxis against Pneumocystis jirovecii pneumonia (PJP). Summary Serial biopsies taken over a 10-month period showed a change from active C4d-positive ABMR, which was characterized by pronounced microvascular inflammation, to chronic postrejection changes. Active rejection resolved under daratumumab therapy. Case 2 Baseline and transplant course We present the case of a nine-year-old boy with end-stage kidney disease due to genetically proven nephronophthisis. His clinical characteristics are summarized in Table 2 . He underwent a deceased-donor KTx at the age of 2, following 2 years of peritoneal dialysis. Pretransplant immunological assessment revealed no HLA antibodies and all cell cultures were negative for lymphocyte toxic crossmatches. The HLA mismatch score (A–B–C–DRB1–DQB1) was 1–2–2–1–2. Table 2:Clinical and laboratory characteristics of two pediatric kidney transplant recipients with ABMR before, at the time of diagnosis, and after treatment with daratumumab. The table summarizes underlying kidney disease, time since transplantation, serum creatinine and eGFR at the respective time points, as well as changes in urinary albumin excretion. Furthermore, IgG levels and DSA-MFI values before and after daratumumab therapy are shown. Both patients following treatment, accompanied by improvements in proteinuria and stabilization of graft function. They also demonstrated a marked reduction in IgG levels after daratumumab therapy.Patient 1Patient 2Underlying diseaseRenal displasiaNephronophtiseYears after KTx87Creatinine before ABMR9055Creatinine at time point of ABMR12951Creatinine after therapy with daratumumab11978eGFR before ABMR (ml/min/1.73 m2 bs)5584eGFR at time point of ABMR (ml/min/1.73 m2 bs)3691eGFR after therapy with daratumumab (ml/min/1.73 m2 bs)4062Albumin in urine at time point of ABMR (mg/g creatinine)11534308Albumin in urine after therapy with daratumumab (mg/g creatinine)81174IgG before therapy with daratumumab (g/l)11.6910.89IgG after therapy with daratumumab (g/l)5.093.35DSA-MFI values before treatment with daratumumab242526 069DSA-MFI values after treatment with daratumumabNegative8614 Clinical and laboratory characteristics of two pediatric kidney transplant recipients with ABMR before, at the time of diagnosis, and after treatment with daratumumab. The table summarizes underlying kidney disease, time since transplantation, serum creatinine and eGFR at the respective time points, as well as changes in urinary albumin excretion. Furthermore, IgG levels and DSA-MFI values before and after daratumumab therapy are shown. Both patients following treatment, accompanied by improvements in proteinuria and stabilization of graft function. They also demonstrated a marked reduction in IgG levels after daratumumab therapy. Table 3:Longitudinal histopathological findings according to Banff classification 2022, DSA levels (DSA-MFI), and dd-cfDNA in our two pediatric cases at baseline and during follow-up biopsies.Case 1BaselineAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3DSA-MFIi0ci0ti02425t0ct1i-IFTA3v0cv1t-IFTA0g3cg2pvl0ptc3ptcml0ah0C4d1mm33 monthsAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3DSA-MFIi1ci0ti0neg.t0ct1i-IFTA3v0cv1t-IFTA0g3cg2pvl0ptc3ptcml0ah0C4d1mm36 monthsAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3DSA-MFIi1ci1ti1neg.t0ct1i-IFTA1v0cv0t-IFTA0g0cg2pvl0ptc2ptcml0ah1C4d0mm310 monthsAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3dd-cfDNAi0ci1ti11%t0ct1i-IFTA3v0cv0t-IFTA1g0cg2pvl0ptc1ptcml0ah2C4d0mm3Case2BaselineAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3DSA-MFIi2ci0ti226 069t1ct1i-IFTA0v0cv0t-IFTA0g1cg3pvl0ptc2ptcml0ah0C4d0mm33 monthsAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3i1ci0ti1t0ct1i-IFTA0v0cv0t-IFTA0g1cg3pvl0ptc3ptcmlah1C4d0mm37 monthsAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3i3ci3ti3t1ct3i-IFTA3v0cv3t-IFTA2g1cg1pvl0ptc2ptcml0ah0C4d0mm310 monthsAcuteGrade 0–3ChronicGrade 0–3Acute and chronicGrade 0–3DSA-MFIdd-cfDNAi0ci0ti086141%t0ct0i-IFTA0v0cv0t-IFTA0g0cg0pvl0ptc0ptcmlah2C4d0mm3 Longitudinal histopathological findings according to Banff classification 2022, DSA levels (DSA-MFI), and dd-cfDNA in our two pediatric cases at baseline and during follow-up biopsies. Induction therapy consisted of basiliximab, followed by maintenance immunosuppression with tacrolimus, everolimus, and corticosteroids. Post-transplant, graft function improved rapidly, with serum creatinine levels declining from 720 to 30 µmol/l (eGFR, 87 ml/min/1.73 m2). However, due to insufficient tacrolimus trough levels, the immunosuppressive therapy was switched to CSA, prior to the appearance of DSAs. Oral corticosteroids were continued for 3 years. No protocol biopsy was performed. Four years after KTx, the immunosuppressive regimen was modified from CSA and everolimus to CSA and mycophenolate mofetil due to recurrent respiratory tract infections. During long-term follow-up, graft function remained stable (eGFR 93–110 ml/min/1.73 m2). Development and diagnosis of ABMR The first screening for DSAs was performed 12 months after transplantation and was negative. HLA typing at that time revealed the following antigens: HLA-A02, HLA-B07, HLA-B62, HLA-C01, HLA-C07, HLA-DRB116, HLA-DQ5, and HLA-DQ8. De novo DSAs targeting HLA-DQ5 were first detected 3 years post-transplant (in 2021) and remained persistently positive for the subsequent 7 years. Following the detection of DSA, no modifications were made to the maintenance immunosuppression regimen, and no additional treatments were administered at that time. Non-HLA antibodies (MHC class I-related chain, ETAR, and AT1R) were first detected 1 year after transplantation, with titers exceeding the upper detection limit (>40 U/ml). Despite the persistence of DSAs, kidney function remained relatively stable, with an eGFR fluctuating between 62 and 80 ml/min/1.73 m2. Seven years post-transplant, the patient developed marked albuminuria (1962 mg/g creatinine), but there was no concomitant rise in serum creatinine. A kidney biopsy at this point revealed active and chronic ABMR according to the Banff criteria, with persistent DSA targeting HLA-DQ5. Prior therapies Prior to the diagnosis of manifest ABMR, no specific antibody-targeted therapies had been administered. At the time of ABMR diagnosis, treatment consisted of high-dose corticosteroid pulse therapy. Daratumumab regimen In addition to steroid pulses, which were administered as part of our standard treatment protocol for ABMR and not due to an associated T-cell-mediated rejection, daratumumab therapy was initiated (Fig. 3). Daratumumab was administered weekly (16 mg/kg body weight) for the first five doses, followed by eight additional doses given monthly. Prior to administration, the patient received premedication with prednisolone and clemastine. Clinical course of Patient 2 following the diagnosis of ABMR and treatment with daratumumab. The figure shows the trajectory of eGFR (green), serum IgG (turquoise), DSA-MFI (black), and urinary albumin-to-creatinine ratio (blue) in relation to daratumumab therapy (orange bars). IgG levels progressively decreased with repeated daratumumab doses, while albuminuria and DSA-MFI showed substantial improvement over time. eGFR remained relatively stable with mild fluctuations during follow-up.. Baseline biopsy (ABMR diagnosis, Table 3) Active and chronic active ABMR with mild glomerulitis (g1), moderate peritubular capillaritis (ptc2), and severe transplant glomerulopathy (cg3). Chronic tubulointerstitial injury was minimal (ci0, ct1). Mild tubulitis (t1) and interstitial inflammation (i2) were present without evidence of vascular rejection (v0). Mesangial matrix expansion was pronounced (mm3). C4d staining was negative (C4d0). DSA-MFI was markedly elevated at 26 069. Three months after daratumumab initiation Persistent acute and chronic active ABMR with stable mild glomerulitis (g1) and progression of peritubular capillaritis (ptc3), while severe transplant glomerulopathy persisted (cg3). Chronic injury remained limited (ci0, ct1), with mild arteriolar hyalinosis now detectable (ah1). C4d staining remained negative (C4d0). Chronic injury remained limited (∼5% IFTA). No immune complex deposits, T cell-mediated rejection (TCMR), or viral infection were identified. Seven months after daratumumab initiation Chronic active ABMR with advanced chronic injury, including severe interstitial fibrosis and tubular atrophy (ci3, ct3, ti3) and advanced vascular sclerosis (cv3). Moderate peritubular capillaritis (ptc2) and mild glomerulitis (g1) persisted, whereas transplant glomerulopathy was less prominent (cg1). Interstitial inflammation and tubulitis increased (i3, t1). C4d staining remained negative (C4d0). Electron microscopy additionally demonstrated endothelial swelling, double contours of the glomerular basement membrane, and subendothelial electron-dense deposits suggestive of a superimposed immune-complex-mediated process. Ten months after daratumumab initiation The biopsy was performed 3 months after the end of daratumumab treatment. Complete histological resolution of active and chronic active ABMR with absent glomerulitis (g0), absent peritubular capillaritis (ptc0), and no residual transplant glomerulopathy (cg0). C4d staining remained negative (C4d0). Chronic injury parameters normalized (ci0, ct0, ti0). Only moderate arteriolar hyalinosis persisted (ah2), consistent with chronic calcineurin inhibitor-related vascular remodeling. Chronic injury was minimal (<1% IFTA). DSA-MFI decreased to 8614 and dd-cfDNA was 1%. During follow-up, serum creatinine remained stable and albuminuria markedly improved under therapy. DSA against HLA-DQ5 persisted at low levels. No infusion-related reactions, cytopenias, or infectious complications were observed during daratumumab treatment. The patient developed reduced IgG levels requiring immunoglobulin substitution therapy. Additionally, cotrimoxazole was administered as prophylaxis against PJP. Following initiation of daratumumab therapy, dd-cfDNA was measured at 1%. The measurements were performed only at later follow-up time points, as this recently established and resource-intensive assay is currently primarily used at our center for surveillance of rejection recurrence rather than for serial monitoring of therapeutic response to daratumumab. Summary This case illustrates the progression of late-onset DQ-DSA-associated acute ABMR with the persistence of HLA and non-HLA antibodies following pediatric KTx. Despite the presence of advanced chronic histological injury throughout the course of the disease, daratumumab therapy was associated with the complete resolution of active and chronic ABMR features, C4d negativity, regression of transplant glomerulopathy, and histological stabilization. eGFR was stabilized (60 ml/min/1.73 m2) at 10 months after initiation of daratumumab therapy. These findings emphasize the significant response to plasma cell-targeted therapy, even in the presence of long-standing antibody-mediated injury. DISCUSSION The histopathological courses observed in this case series are consistent with the aforementioned publications, in which daratumumab is described as a potential rescue therapy for refractory, chronic, and acute ABMR. As demonstrated in previous reports from the field of adult transplantation (see, e.g. the works of Doberer et al., Zhu et al., and Lye) [6, 7, 9], a reduction in DSA levels, improvement in microvascular inflammation, and variable effects on chronic structural damage under CD38-targeted therapy have been observed. This targeted approach aligns with a recent perspective by Böhmig et al., who highlighted the lack of robust evidence supporting many conventional ABMR therapies and emphasized the optimization of baseline immunosuppression. Consequently, CD38-directed strategies have emerged as a rational potential first-line approach for late AMR, particularly in episodes occurring >6 months post-transplant and primarily driven by de novo DSA [3]. Importantly, daratumumab may affect immune cell populations beyond plasma cells, as illustrated by a reported case of T-cell-mediated rejection following pretransplant daratumumab exposure. This observation underscores the need for careful monitoring of cellular alloimmune responses when applying CD38-targeted therapies in transplantation. The present study extends these observations to the pediatric population and, to the best of the authors’ knowledge, provides the first documentation of serial protocol biopsies to assess treatment dynamics in children. The serial biopsies demonstrate a favorable response of kidney transplant tissue to treatment with daratumumab, indicating both the extent and timing of the observed histological improvement. The decline in C4d positivity over time indicates the effective suppression of complement-activating antibody mechanisms, which may suggest a transition from active to inactive alloimmune damage. The presence of immune complexlike ultrastructural features in one patient underscores the complexity of the overlapping pathology and suggests that immune-complex-mediated mechanisms may coexist with ABMR pathways in selected cases. This is also surprising because Patient 2 had not previously had ABMR and had had a completely unremarkable course after KTx. It is also noteworthy that Patient 2 was distinguished by his pronounced proteinuria, accompanied by relatively stable graft function. Patient 1 had a documented history of ABMR, which had been treated with rituximab and immunoglobulins. This could also explain the different response phenotypes observed: a gradual transition to chronic scarring in Patient 1 versus almost complete histological remission in Patient 2 underlining the potential variability of treatment courses and raising questions regarding patient-specific determinants of response. In Patient 1, no DSAs were detectable after therapy with daratumumab. In Case 2, the DSA-MFI significantly decreased from 26 069 to 8614 following treatment, and subsequently persisted at these lower levels. The long-term development of the DSA course remains to be ascertained. Renal function stabilized in both patients at the level it was when ABMR initially occurred. Current data suggest that cell-free DNA from donors can serve as a sensitive companion biomarker for monitoring response to treatment with daratumumab, as it shows dynamic changes that precede a reduction in DSAs. Such biomarkers may complement histology and serology in assessing therapeutic efficacy and determining individual treatment strategies, and could serve as progression parameters [19]. The optimal frequency and scheduling of daratumumab administration remain to be elucidated. Patient 1 received five doses of daratumumab at weekly intervals and six doses at four-week intervals. Patient 2 received three doses at weekly intervals and 10 doses at monthly intervals. Further elucidation is only to be had through the medium of long-term observation. A recent pilot study combining daratumumab with subsequent interleukin-6 receptor blockade has shown that DSAs are permanently reduced and graft function stabilizes in cases of late ABMR. These results support the idea that the combined targeting of antibody-producing plasma cells could permanently improve the response to ABMR treatment [20]. The significance of this study is limited by three factors. First, the sample size is small. Second, the design is retrospective. Third, the evaluation of biomarkers is incomplete. Consequently, the results must be interpreted with caution and validated in larger prospective cohorts. When interpreting the therapeutic response in Case 2, a cautious assessment of the consecutive biopsy findings is warranted. Any apparent discrepancies across biopsies regarding chronic lesions such as IFTA, glomerulosclerosis, or transplant glomerulopathy are best explained by the known patchy nature of these lesions leading to sampling variability, rather than a true reversibility of established chronic damage. Furthermore, it is noteworthy that chronic active ABMR often initially presents with progressive glomerular proteinuria, while graft dysfunction may become apparent only later in the disease course. In this context, while daratumumab may effectively reduce microvascular inflammation, its primary role concerning established chronic injury is stabilization rather than reversal. Daratumumab has been identified as a potential rescue option for refractory, chronic ABMR in pediatric transplant medicine. Serial biopsies have been demonstrated to be a reliable method for evaluating response to treatment and informing treatment decisions. The necessity for controlled studies is paramount in order to define the optimal timing, dosage, and long-term safety in children.